UNSPSC 51272001: Methohexital or methohexitone

This classification denotes a barbiturate with the molecular formula C14H18N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier E5B8ND5IPE, chemically known as 2,4,6(1h,3h,5h)-pyrimidinetrione, 1-methyl-5-(1-methyl-2-pentynyl)-5-(2-propenyl)-, (+-)- but generally known as methohexital, which bears US NIH Compound Identifier 9034. European Medicines Agency schedules Methohexital in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14540MIG.

UNSPSC 51272001 Methohexital or methohexitone is a Commodity code that shows minimal alignment between its nominal scope and recent state and local procurement activity. The three recent opportunities posted under this code involve naloxone procurement, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and OTC products—none of which are methohexital or related barbiturate anesthetics. The code appears to be a tagging mismatch in the state and local procurement systems rather than an active category for the specific drug it nominally describes. Issuing bodies across these opportunities span county health departments, state health and human services commissions, and multistate cooperative purchasing alliances, but the work being solicited bears no consistent relationship to the code's stated substance.

Geographic activity is scattered across Florida, Texas, and Minnesota with limited concentration. Seminole County, Florida posted an IFB on June 30, 2026 (due July 26, 2023—an apparent date error in the source) for naloxone and drug deactivation systems with quarterly deliveries to the county community health building. The Texas Health and Human Services Commission issued a Request for Information on April 3, 2026 to explore direct-to-manufacturer prescription arrangements outside traditional pharmacy benefit manager channels. The Minnesota Multistate Cooperative Purchasing Alliance issued an RFP on January 20, 2026 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products across participating state and local government facilities. The code shows little relevant recent activity and does not reliably capture state and local demand for the substance it nominally describes.